Nachrichten zur NANOBIOTIX INH. EO-,03 Aktie

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

PARIS and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the…

NANOBIOTIX to Participate in Multiple Investor Conferences in November

~ Guggenheim’s Inaugural Healthcare Innovation Conference, Nov 11-13 ~…

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the…

Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript

…

Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript

…

Nanobiotix to Present at Upcoming Investor Conferences in March

PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the…

Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets

PARIS and CAMBRIDGE, Mass., Dec. 26, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX –…

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.

PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the…

Nanobiotix S.A. (NBTX) Q3 2023 Earnings Call Transcript

…

Nanobiotix S.A. 2023 Q3 - Results - Earnings Call Presentation

…

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET Conference call…

NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M

PARIS and CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the…

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

PARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the…

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the…

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data…

NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology

Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CEST Conference call and live webcast Thursday,…

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research…

Nanobiotix GAAP EPS of €0.80, revenue of €3.3M

…

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

PARIS and CAMBRIDGE, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the…

NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023

PARIS and CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the Company),…

ADRs End Mostly Lower, Nanobiotix and Taiwan Semiconductor Manufacturing Trade Actively

ADRs End Mostly Lower, Nanobiotix and Taiwan Semiconductor Manufacturing Trade Actively...…

Wall Street: Kursgewinne zum Wochenauftakt – Amazon, Tesla und Nanobiotix im Fokus

Zum Wochenauftakt hat die Wall Street leichte Kursgewinne verzeichnet. In den den ersten Handelsminuten ging es für den Dow Jones…

Nanobiotix Shares Soar on Licensing Deal With J&J Unit >NBTX

Nanobiotix Shares Soar on Licensing Deal With J&J Unit >NBTX...…

Nanobiotix’s stock soars after entering licensing, development deal with J&J’s Janssen Pharmaceutica

Shares of Nanobiotix SA NBTX shot up 52.1% toward a 17-month high in premarket trading Monday, after the France-based biotechnology…

Nanobiotix up 54% on licensing agreement for development of Radioenhancer NBTXR3

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 6-K Nanobiotix S.A. For: Jul 10

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biggest stock movers today: Icahn Enterprises, Nanobiotix and more

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

PARIS and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the…

Form 6-K Nanobiotix S.A. For: Jun 08

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nanobiotix, Veeva top healthcare gainers; Lexicon, Adicet among losers

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nanobiotix reports Q1 results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update

Reported €30.2 million in cash and cash equivalents as of March 31, 2023 Reported €30.2 million in cash and cash…

Nanobiotix Shares Pull Back From Friday Highs, Drop 15%

Nanobiotix Shares Pull Back From Friday Highs, Drop 15%...…

Nanobiotix Shares Triple to Hit 52-Week High After Entering Final Negotiations For Cancer Drug

Nanobiotix Shares Triple to Hit 52-Week High After Entering Final Negotiations For Cancer Drug...…

Nanobiotix stock more than triples, after biotech enters final negotiations with ‘major’ drug maker on development of cancer treatment

The U.S.-listed shares of Nanobiotix S.A. NBTX blasted 221.7% higher on massive volume Friday, to pace all gainers trading on…

NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company

Company agreed to term sheet as of May 3, 2023 Company agreed to term sheet as of May 3, 2023...…

dpa-AFX ProFeed